Biogen (BIIB) reported 4th Quarter December 2018 earnings of $6.99 per share on revenue of $3.5 billion. The consensus earnings estimate was $6.72 per share on revenue of $3.4 billion. The Earnings Whisper number was $6.83 per share. Revenue grew 6.6% on a year-over-year basis.
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers,
develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.